Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the synthesis of catecholamines, including dopamine, norepinephrine, and epinephrine. It catalyzes the conversion of L-tyrosine to L-DOPA. TH is a homotetramer with each subunit containing a regulatory domain, a catalytic domain with a non-heme iron center, and a tetramerization domain. Its activity is regulated by feedback inhibition from catecholamines and phosphorylation. Mutations in TH are associated with Dopa-responsive dystonia and other neurological disorders, making it a target for therapeutic intervention.
Inhibition of tyrosine hydroxylase enzyme activity, reducing catecholamine production.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine Hydroxylase (None).